Potential Adverse Developmental and Nutritional Consequences of Helicobacter Pylori Infection in Israeli Children
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Amit Hochberg, MD
- Phone Number: 972-4-6304320
- Email: amit.hochberg@gmail.com
Study Locations
-
-
-
Hadera, Israel, 38100
- Hillel Yaffe Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Informed consent by parents/guardians and children
Exclusion Criteria:
- Growth retardation history
- History of prior therapy for H. pylori irradiation
- Hematological disorders
- Developmental delays
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
H.pylori positive children
Healthy children, 6-12 years old, will undergo screening for H. pylori infection by measuring anti-H.
pylori and CagA IgG antibodies in the serum.
The status of H. pylori infection will be confirmed using breath test (UBT).
Children will be classified as i) H. pylori negative, if they test negative on UBT ii) H. pylori positive- CagA negative, if they test positive on UBT, but lack serum CagA IgG antibodies iii) H. pylori positive- CagA positive, if they are positive for H. pylori on UBT and CagA IgG antibodies.
|
|
H.Pylori negative children
Healthy children, 6-12 years old, will undergo screening for H. pylori infection by measuring anti-H.
pylori and CagA IgG antibodies in the serum.
The status of H. pylori infection will be confirmed using breath test (UBT).
Children will be classified as i) H. pylori negative, if they test negative on UBT ii) H. pylori positive- CagA negative, if they test positive on UBT, but lack serum CagA IgG antibodies iii) H. pylori positive- CagA positive, if they are positive for H. pylori on UBT and CagA IgG antibodies.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in means of differences in height
Time Frame: Two years
|
The means of the differences in height for age Z score between baseline and follow-up visits
|
Two years
|
|
Changes in means of differences in weight
Time Frame: Two years
|
The means of the differences in weight for age Z score between baseline and follow-up visits
|
Two years
|
|
Changes in means of differences in body mass index
Time Frame: Two years
|
The means of the differences in body mass index for age Z score between baseline and follow-up visits
|
Two years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Iron Biomarkers
Time Frame: Two years
|
The means of the differences in iron biomarkers (hemoglobin, ferritin, iron) between baseline and follow-up visits
|
Two years
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Intelligence quotient (IQ) scores
Time Frame: Two years
|
Changes in full-Scale IQ scores and-sub-scores on WISC test between baseline and 24-months follow-up visit: will be defined as the means of the differences of these scores.
|
Two years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Disease Attributes
- Hematologic Diseases
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Anemia, Hypochromic
- Anemia
- Iron Metabolism Disorders
- Infections
- Communicable Diseases
- Anemia, Iron-Deficiency
- Helicobacter Infections
Other Study ID Numbers
Other Study ID Numbers
- HYMC-0093-15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.